{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104986","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.849555+00:00","generated_at":"2026-05-17T17:58:24.542350+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IN8bio reports Q2 net loss of $5.1M; 4-year PFS milestone in glioblastoma trial","bullets":["Net loss $5.1M ($1.24/sh) vs $8.6M ($5.51/sh) in Q2 2024; R&D expenses down to $2.5M from $5.2M.","Cash $13.2M as of June 30, 2025 (up from $10.2M year ago); runway extended into June 2026.","INB-200 trial patient surpasses 4 years without progression; mPFS 16.1 months for multi-dose patients (standard of care 6.9 months).","Preclinical data at ASGCT 2025: INB-619 achieves complete B cell depletion in lupus samples without significant inflammatory cytokines.","Received Host Region USA East Abstract Award at ISCT 2025 for DeltEx manufacturing platform."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104986","json":"https://secwatch.observer/filing/0000950170-25-104986.json","markdown":"https://secwatch.observer/filing/0000950170-25-104986.md","text":"https://secwatch.observer/filing/0000950170-25-104986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017025104986/0000950170-25-104986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017025104986/inab-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:58:24.542350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}